This review article aimed to performa comprehensive review and evaluation of the potential of radionuclides and radiopharmaceuticals used in breast cancer treatment in preclinical studies conducted in the last five years.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Radiopharmaceutical therapy (RPT) is an effective and safe treatment for many types of cancer.
📊
Key Findings & Data:These treatments ensure that a concentrated dose is delivered to the targeted tumor tissue while preserving the normal tissues surrounding the tumor.
💡
Conclusion & Impact:This review article aimed to performa comprehensive review and evaluation of the potential of radionuclides and radiopharmaceuticals used in breast cancer treatment in preclinical studies conducted in the last five years.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Radiopharmaceutical therapy (RPT) is an effective and safe treatment for many types of cancer. RPT acts by binding radioactive atoms to tumor-associated antigens, monoclonal antibodies, nanoparticles, peptides, and small molecules. These treatments ensure that a concentrated dose is delivered to the targeted tumor tissue while preserving the normal tissues surrounding the tumor. Given these features, RPT is superior to traditional methods. This review article aimed to performa comprehensive review and evaluation of the potential of radionuclides and radiopharmaceuticals used in breast cancer treatment in preclinical studies conducted in the last five years.
🔖
Cite This Article
GÜLEÇ, B. A., YURT, F. (2022). Treatment with Radiopharmaceuticals and Radionuclidesin Breast Cancer: Current Options. European Journal of Breast Health, Cilt: 17 - Sayı: 3, 214–219. https://ajindex.com/articles/510704
World Health Organization. Cancer Report, September 2018. Available from: https://www.who.int/health-topics/cancer#tab=tab_1 [Crossref] 2. Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health 2019
(PMID: 31854162) [Crossref] 3. Kayano D, Kinuya S. Current consensus on 131I-MIBG therapy. Nucl Med Mol Imaging 2018
(PMID: 30100938) [Crossref] 4. Das S, Al-Toubah T, El-Haddad G, Strosberg J.177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2019
(PMID: 31652074) [Crossref] 5. Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M.177LuPSMA radioligand therapy for prostate cancer. J Nucl Med 2017
(PMID: 28663195) [Crossref] 6. Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced lung carcinoids. Clin Lung Cancer 2019
e376-e392. doi: 10.1016/j.cllc.2019.02.007 (PMID: 30910575) [Crossref] 7. Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA). Hematol Oncol Stem Cell Ther 2018
(PMID: 29406240) [Crossref] 8. Tafreshi NK, Doligalski ML, Tichacek CJ, Pandya DN, Budzevich MM, El-Haddad G, et al. Development of targeted alpha particle therapy for solid tumors. Molecules 2019
(PMID: 31779154) 9. Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med 2019
13S-19S. doi: 10.2967/jnumed.118.220566 (PMID: 31481583) [Crossref] 10. Yeong CH, Cheng MH, Ng KH. Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B 2014
(PMID: 25294374) [Crossref] 11. Sgouros G. Radiopharmaceutical therapy. Health Phys 2019
(PMID: 30585960) [Crossref] 12. Jadvar H. Targeted α-therapy in cancer management: synopsis of preclinical and clinical studies. Cancer Biother Radiopharm 2020
(PMID: 32202923) [Crossref] 13. Williams WSC, Nuclear and particle physics. 1st ed. Oxford: Oxford University
[Crossref] 14. Reed AB. The history of radiation use in medicine. J Vasc Surg 2011
53(Suppl 1): 3S-5S. doi: 10.1016/j.jvs.2010.07.024 (PMID: 20869835) [Crossref] 15. Ferrier MG, Radchenko V, Wilbur S. Radiochemical aspects of alpha emitting radionuclides for medical application. Radiochim Acta 201